uniQure N.V. will announce Q3 2026 financial results on November 4, followed by a conference call at 8:30 a.m. ET.
Quiver AI Summary
uniQure N.V., a gene therapy company focused on developing treatments for serious medical conditions, will announce its third quarter 2026 financial results on November 4, 2026, prior to market opening. Following the results, management will hold a conference call at 8:30 a.m. ET, which will be available via webcast on the company's website. A replay of the call will be accessible for 90 days. Analysts who wish to ask questions during the call can join by calling designated numbers and using a specific conference ID. uniQure is recognized for its significant achievement in gene therapy, particularly for hemophilia B, and continues to work on other therapies targeting diseases such as Huntington's disease and Fabry disease.
Potential Positives
- uniQure is reporting a significant milestone with the upcoming financial results for Q3 2026, showcasing transparency and accountability to investors.
- The company's gene therapy for hemophilia B has received approvals, marking a historic achievement in genomic medicine.
- uniQure is actively advancing a diverse pipeline of proprietary gene therapies targeting multiple severe diseases, indicating robust growth potential and innovation.
Potential Negatives
- None
FAQ
When will uniQure report its third-quarter financial results?
uniQure will report its third-quarter 2026 financial results on Wednesday, November 4, 2026, before market open.
How can I access the conference call for the financial results?
The conference call can be accessed by dialing (646) 307-1963 or toll-free (800) 715-9871, with conference ID 5075555.
What time is the conference call scheduled?
The conference call is scheduled for 8:30 a.m. ET on November 4, 2026.
Where can I find the webcast of the event?
The webcast can be found in the Events & Presentations section on uniQure’s website at www.uniqure.com.
What is uniQure's focus in gene therapy?
uniQure focuses on developing transformative gene therapies for severe conditions like hemophilia, Huntington's disease, and Fabry disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$QURE Insider Trading Activity
$QURE insiders have traded $QURE stock on the open market 34 times in the past 6 months. Of those trades, 0 have been purchases and 34 have been sales.
Here’s a breakdown of recent trading of $QURE stock by insiders over the last 6 months:
- MATTHEW C KAPUSTA (CEO, Managing Director) has made 0 purchases and 13 sales selling 262,594 shares for an estimated $12,094,837.
- JACK KAYE has made 0 purchases and 5 sales selling 31,100 shares for an estimated $1,341,745.
- MADHAVAN BALACHANDRAN has made 0 purchases and 5 sales selling 23,678 shares for an estimated $858,915.
- KYLIE O'KEEFE (Chief Customer & Strat Officer) sold 15,936 shares for an estimated $431,228
- ROBERT GUT has made 0 purchases and 4 sales selling 10,278 shares for an estimated $270,485.
- JEANNETTE POTTS (Chief Legal Officer) sold 5,237 shares for an estimated $144,907
- WALID ABI-SAAB (Chief Medical Officer) sold 1,434 shares for an estimated $67,197
- LEONARD E POST sold 1,993 shares for an estimated $53,930
- DAVID D. MEEK sold 1,993 shares for an estimated $53,930
- JEREMY P. SPRINGHORN sold 1,993 shares for an estimated $53,930
- RACHELLE SUZANNE JACQUES sold 1,993 shares for an estimated $53,930
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$QURE Hedge Fund Activity
We have seen 158 institutional investors add shares of $QURE stock to their portfolio, and 107 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 4,867,755 shares (+inf%) to their portfolio in Q2 2026, for an estimated $224,208,795
- ABERDEEN GROUP PLC removed 2,458,269 shares (-46.3%) from their portfolio in Q2 2026, for an estimated $113,227,870
- RTW INVESTMENTS, LP added 1,355,216 shares (+52.4%) to their portfolio in Q2 2026, for an estimated $62,421,248
- TWO SIGMA INVESTMENTS, LP removed 1,213,847 shares (-45.4%) from their portfolio in Q2 2026, for an estimated $55,909,792
- SIREN, L.L.C. removed 1,000,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $46,060,000
- JANE STREET GROUP, LLC added 974,488 shares (+153.2%) to their portfolio in Q2 2026, for an estimated $44,884,917
- BOXER CAPITAL MANAGEMENT, LLC added 841,300 shares (+127.1%) to their portfolio in Q2 2026, for an estimated $38,750,278
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$QURE Analyst Ratings
Wall Street analysts have issued reports on $QURE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/29/2026
To track analyst ratings and price targets for $QURE, check out Quiver Quantitative's $QURE forecast page.
$QURE Price Targets
Multiple analysts have issued price targets for $QURE recently. We have seen 6 analysts offer price targets for $QURE in the last 6 months, with a median target of $66.5.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $80.0 on 06/29/2026
- Uy Ear from Mizuho set a target price of $68.0 on 06/25/2026
- Luca Issi from RBC Capital set a target price of $65.0 on 06/18/2026
- Joseph Schwartz from Leerink Partners set a target price of $70.0 on 06/18/2026
- Eliana Merle from Barclays set a target price of $65.0 on 06/18/2026
- Salveen Richter from Goldman Sachs set a target price of $46.0 on 06/18/2026
Full Release
LEXINGTON, Mass. and AMSTERDAM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report third quarter 2026 financial results before market open on Wednesday, November 4, 2026. Management will then host a conference call at 8:30 a.m. ET.
The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations , and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com
uniQure Contacts:
|
FOR INVESTORS:
|
FOR MEDIA: |
| Chiara Russo | Tom Malone |
| Direct: 781-491-4371 | Direct: 339-970-7558 |
| Mobile: 617-306-9137 | Mobile:339-223-8541 |
| [email protected] | [email protected] |
